Anticoagulants
High-yield Verified · Oct 2026Every anticoagulant is defined by where it enters the cascade — upstream at vitamin K-dependent synthesis (warfarin), through antithrombin (heparin, LMWH, fondaparinux), or directly at Xa or thrombin (the -xabans, dabigatran, argatroban, bivalirudin) — and that point predicts its onset, monitoring, HIT risk and antidote.
Nursing view → administration, monitoring and patient teaching
Compare: Antithrombotics compared — anticoagulants, antiplatelets and thrombolytics →
Drugs
Mechanism
Interrupt the coagulation cascade — warfarin inhibits synthesis of vitamin-K-dependent factors (II, VII, IX, X); heparin/LMWH potentiate antithrombin, and fondaparinux uses antithrombin to inhibit factor Xa selectively; DOACs directly inhibit factor Xa (apixaban, rivaroxaban, edoxaban) or thrombin (dabigatran); argatroban and bivalirudin are IV direct thrombin inhibitors.
The cascade as a set of drug targets
Clotting factors circulate as inactive zymogens that are activated into serine proteases, each cleaving the next. In the extrinsic pathway, tissue factor released on vascular injury activates factor VII, and VIIa activates factor X. In the intrinsic pathway, factor XII is activated by exposed endothelial collagen and drives XI → IX; IXa, with cofactor VIII, activates factor X. The PT reflects the extrinsic pathway and the PTT the intrinsic one.
In the common pathway, factor Xa — with factor V as cofactor — converts prothrombin (II) to thrombin (IIa). Thrombin turns fibrinogen into fibrin and also activates factor XI, cofactors V and VIII and factor XIII, which builds a stable fibrin mesh.
The body has its own brakes: antithrombin reduces thrombin formation and the amount of active factor X, and proteins C and S inactivate factors V and VIII. Heparin-type drugs exploit antithrombin; warfarin unintentionally lowers proteins C and S.
Warfarin and the vitamin K cycle
Factors II, VII, IX and X — and proteins C and S — only work after γ-carboxylation: a carboxylase adds carboxyl groups to glutamate residues, creating γ-carboxyglutamate that chelates calcium. The reaction uses reduced vitamin K and leaves vitamin K epoxide, which vitamin K epoxide reductase (VKOR) recycles. Warfarin inhibits the VKORC1 subunit, depleting functional vitamin K, so the liver releases factors that cannot work.
Warfarin does not touch factors already circulating, so its effect follows their half-lives: factor VII 4–6 h, IX 24 h, X 48–72 h, II 60 h; proteins C and S about 8 h and 30 h. The INR rises early (factor VII), but onset takes 24–72 h and the peak 5–7 days. Because protein C falls before the clotting factors, the first days carry a transient hypercoagulable state — the setting of warfarin skin necrosis, especially with protein C or S deficiency — which is why heparin overlaps warfarin at the start.
Antithrombin-dependent drugs — and why heparin causes HIT
Heparin binds antithrombin and changes its shape, greatly enhancing its ability to inactivate thrombin and factor Xa. Enoxaparin binds antithrombin through a specific pentasaccharide sequence, but its shorter chains give more activity against Xa and less against thrombin. Fondaparinux is that synthetic pentasaccharide alone: antithrombin-mediated, selective factor Xa inhibition.
Heparin-induced thrombocytopenia comes from platelet factor 4 (PF4). Released from platelet α-granules, positively charged PF4 binds negatively charged heparin, and the heparin–PF4 complex can provoke antibodies. HIT occurs when IgG bound to that complex engages platelet Fc receptors, activating platelets, which release more PF4 — a loop that drives thrombosis while macrophages clear the antibody-coated platelets (the falling count). Up to half of patients develop thromboembolic complications.
Fondaparinux binds antithrombin but not PF4 and does not react with heparin-induced antibodies, so it does not cause HIT; the risk with LMWH is lower than with unfractionated heparin.
Direct inhibitors and the antidotes that mirror them
The direct factor Xa inhibitors — apixaban, rivaroxaban, edoxaban — and the direct thrombin inhibitors need no antithrombin. Dabigatran is an oral prodrug: esterases convert dabigatran etexilate to active dabigatran, a competitive thrombin inhibitor. Argatroban (reversibly binding the thrombin active site) and bivalirudin (a 20-amino-acid peptide) are IV thrombin inhibitors used when heparin is off the table — in HIT, or during PCI.
Each antidote is built on the drug’s mechanism. Protamine, a strongly cationic arginine-rich protein, forms a salt with strongly anionic heparin (reversal of LMWH is only partial). Idarucizumab is a humanized antibody fragment that binds dabigatran with higher affinity than dabigatran binds thrombin. Andexanet alfa is an inactive, modified factor Xa that binds and sequesters rivaroxaban and apixaban. Vitamin K restores carboxylation for new factors, while prothrombin complex concentrate supplies factors directly. Argatroban and bivalirudin have no specific antidote; their short half-lives are the safety margin.
Comparing the drugs
Target, route, monitoring and reversal
| Drug | Target | Route | Monitoring | Reversal |
|---|---|---|---|---|
| Warfarin | VKORC1 → no active II, VII, IX, X (and C, S) | Oral | INR | Vitamin K; 4-factor PCC or FFP for bleeding |
| Heparin | Antithrombin → thrombin and Xa | IV or SC | aPTT (or anti-Xa); platelets | Protamine |
| Enoxaparin | Antithrombin → mainly Xa | SC (or IV) | Anti-Xa if renal impairment | Protamine (partial) |
| Fondaparinux | Antithrombin → Xa only | SC | PT/aPTT insensitive; CBC, creatinine | None (no known antidote) |
| Apixaban | Factor Xa (direct) | Oral | No routine test | Andexanet alfa |
| Rivaroxaban | Factor Xa (direct) | Oral; 15 mg and 20 mg tablets with food | No routine test | Andexanet alfa |
| Edoxaban | Factor Xa (direct) | Oral | CrCl before starting (NVAF) | None specific (not covered by andexanet’s label) |
| Dabigatran | Thrombin (direct; prodrug) | Oral | No routine test | Idarucizumab; hemodialysis |
| Argatroban | Thrombin (direct, reversible) | IV | aPTT 1.5–3× baseline | None (short half-life) |
| Bivalirudin | Thrombin (direct, reversible) | IV (PCI) | ACT after the bolus | None (short half-life) |
PCC = prothrombin complex concentrate; FFP = fresh frozen plasma.
Pharmacokinetics at a glance
| Drug | Bioavailability | Half-life | Elimination | Watch |
|---|---|---|---|---|
| Warfarin | Essentially complete | 20–60 h (S 21–43 h, R 37–89 h) | Hepatic; S-warfarin by CYP2C9 | CYP2C9/1A2/3A4 inhibitors and inducers |
| Heparin | IV/SC only | Dose-dependent, short | Reticuloendothelial uptake and hepatic | Low antithrombin (CKD) may alter response |
| Fondaparinux | SC | 17–21 h | Renal, unchanged (up to 77%) | Contraindicated if CrCl < 30 |
| Apixaban | About 50% | About 12 h | Renal about 27%; CYP3A4, P-gp | Combined P-gp + strong CYP3A4 drugs |
| Rivaroxaban | About 66% (20 mg, fasted) | 5–9 h | One-third unchanged in urine; CYP3A4/5, 2J2 | Combined P-gp + strong CYP3A drugs |
| Edoxaban | 62% | 10–14 h | Renal about 50% | P-gp; rifampin |
| Dabigatran | 3–7% (prodrug) | Longer in renal impairment | Mainly renal; 35% protein-bound | P-gp inducers; renal function |
| Argatroban | IV | 39–51 min | Hepatic (CYP3A4/5) | Hepatic impairment slows reversal |
| Bivalirudin | IV | 25 min (longer in renal impairment) | Proteolytic cleavage; renal | About 25% removed by hemodialysis |
Pharmacokinetics
- Warfarin: two enantiomers, one key enzyme — warfarin
- Warfarin is a racemic mixture; S-warfarin is mainly metabolized by CYP2C9 to 7-hydroxywarfarin. Its half-life is 20–60 hours and highly variable (R-warfarin 37–89 h, S-warfarin 21–43 h). Inhibitors of CYP2C9, 1A2 or 3A4 raise the INR and inducers lower it, so the INR is checked closely whenever an interacting drug starts or stops.
- Heparin versus the renally cleared heparinoids — heparin, enoxaparin, fondaparinux
- Unfractionated heparin is cleared by hepatic metabolism and reticuloendothelial uptake, with a dose-dependent half-life, and binds many plasma proteins. Fondaparinux is eliminated unchanged in urine (up to 77% in 72 hours) with a 17–21-hour half-life, so its elimination is prolonged in renal impairment — hence the CrCl < 30 contraindication. Enoxaparin needs a dose change below a CrCl of 30, and anti-Xa levels can monitor it.
- Dabigatran: a prodrug the kidney clears — dabigatran
- Dabigatran etexilate is converted by esterase-catalyzed hydrolysis to dabigatran; absolute bioavailability is only 3–7%. Dabigatran is primarily eliminated by the kidneys and only about 35% protein-bound, so renal impairment raises its activity and half-life, and hemodialysis can remove it. Breaking or opening the capsule raises exposure.
- The factor Xa inhibitors: liver and kidney in different proportions — apixaban, rivaroxaban, edoxaban
- Apixaban (about 50% bioavailable, half-life about 12 h) relies least on the kidney — about 27% of clearance — and is a CYP3A4 and P-gp substrate. Rivaroxaban is about 66% bioavailable fasting at 20 mg, so the 15 mg and 20 mg tablets are taken with food; about one-third is excreted unchanged in urine, and it is a CYP3A4/5, CYP2J2 and P-gp substrate. Edoxaban (62% bioavailable, half-life 10–14 h) is about 50% renally cleared.
- The IV thrombin inhibitors: minutes, cleared differently — argatroban, bivalirudin
- Argatroban is metabolized in the liver (CYP3A4/5) with a terminal half-life of 39–51 minutes; hepatic impairment lowers clearance, so reversal after stopping can take more than 4 hours. Bivalirudin is cleared by proteolytic cleavage and the kidney, with a 25-minute half-life that lengthens in renal impairment; about 25% is removed by hemodialysis.
- Why the warfarin INR lags — warfarin
- Onset is 24–72 hours and the peak effect 5–7 days because existing factors must decay (factor II has a 60-hour half-life). Patients with CYP2C9 *1/*3, *2/*2, *2/*3 or *3/*3 may take more than 2–4 weeks to reach the maximum INR for a given regimen.
Pharmacogenomics
Uses & drug choice
- Atrial fibrillation (stroke prevention)
- Venous thromboembolism (DVT / PE) treatment & prophylaxis
- Warfarin for mechanical heart valves (the DOACs are contraindicated or not recommended)
- Argatroban for heparin-induced thrombocytopenia (prophylaxis or treatment of thrombosis), including during PCI
- Bivalirudin as the anticoagulant during PCI, including in patients with HIT
Adverse effects
- Bleeding — bruising to intracranial or GI hemorrhage
- It is the therapeutic effect taken too far: less thrombin and fibrin wherever a vessel is injured. Warfarin over-anticoagulation shows as a high INR; with argatroban, an unexplained fall in hematocrit or blood pressure may be the first sign.
- Heparin-induced thrombocytopenia
- IgG against the heparin–PF4 complex binds platelet Fc receptors and activates platelets, which release more PF4 and procoagulants; the antibody-coated platelets are cleared, so the count falls while thrombosis rises. Fondaparinux does not cause it.
- Warfarin skin necrosis
- Protein C (half-life about 8 h) falls before factors II, IX and X, creating a transient acquired protein C deficiency and a prothrombotic state, usually in the first week and more often with inherited protein C or S deficiency. Heparin overlap reduces it.
- Stroke after stopping a DOAC (boxed)
- The DOACs act for hours, not days; stopping one without other anticoagulation removes protection quickly, increasing thrombotic events.
- Spinal or epidural hematoma (boxed)
- Anticoagulated blood can collect after neuraxial anesthesia or spinal puncture and compress the cord, causing long-term or permanent paralysis; indwelling catheters, other hemostasis-affecting drugs and traumatic punctures add risk.
- Thrombocytopenia with fondaparinux
- It can occur, including HIT-like thrombocytopenia with thrombosis reported after approval, even though fondaparinux does not bind PF4 or react with heparin-induced antibodies.
- Heparin osteoporosis and hyperkalemia
- Osteopenia and osteoporosis are linked to chronic heparin use, not short courses; hyperkalemia is also reported.
Toxicity & antidote
Warfarin: vitamin K restores γ-carboxylation, but new factors take time, and warfarin’s action outlasts vitamin K — case reports describe patients re-bleeding with a high INR days after it was corrected. Vitamin K is not needed for an elevated INR alone unless it exceeds 10 or there is bleeding; for serious bleeding, 4-factor prothrombin complex concentrate (or 3-factor PCC with fresh frozen plasma) replaces the factors directly.
Heparin: protamine neutralizes it by forming a salt (reversal of LMWH is partial). Dabigatran: idarucizumab binds it; hemodialysis can also remove it. Apixaban and rivaroxaban: andexanet alfa sequesters them (its own boxed warning covers thromboembolic events and cardiac arrest). Argatroban and bivalirudin: there is no antidote — stop the infusion and rely on the short half-life (longer for argatroban in hepatic impairment).
Interactions
Contraindications
- Active clinically significant bleeding — Anticoagulation would worsen an ongoing bleed, which the body cannot control while the cascade is suppressed.
- Spinal puncture or major regional/lumbar block anesthesia (warfarin) — Bleeding into the spinal canal can cause an epidural hematoma and permanent paralysis. For DOACs and LMWH the same risk is a boxed warning rather than a contraindication: the drug must be timed around neuraxial procedures.
- Severe thrombocytopenia or a history of HIT (heparin) — Too few or antibody-affected platelets make bleeding — or, with HIT, dangerous clotting — highly likely.
- Pregnancy (warfarin) — Warfarin crosses the placenta and can cause embryopathy and fetal hemorrhage (it is allowed only with a mechanical heart valve); LMWH is the preferred anticoagulant in pregnancy.
- Mechanical prosthetic heart valve (dabigatran) — Dabigatran is contraindicated with mechanical valves; rivaroxaban and edoxaban are not recommended with them, and warfarin remains the anticoagulant for mechanical valves.
- Fondaparinux: CrCl < 30 mL/min, bacterial endocarditis, fondaparinux-associated antibody-positive thrombocytopenia, or body weight < 50 kg (adult VTE prophylaxis) — Fondaparinux is renally cleared and bleeding risk rises with renal impairment and low body weight; the label also contraindicates it in bacterial endocarditis and in thrombocytopenia with anti-platelet antibodies to fondaparinux.
- Malignant hypertension (warfarin) use caution — Extremely high blood pressure raises the risk of hemorrhagic stroke on warfarin, so malignant hypertension is a labeled contraindication.
High-yield
- Upstream — warfarin stops vitamin K recycling, so new II, VII, IX, X are made inactive: slow onset, INR, vitamin K/PCC to reverse
- Through antithrombin — heparin (thrombin + Xa), LMWH (mostly Xa), fondaparinux (Xa only): aPTT or anti-Xa, protamine for heparin, HIT with heparin
- Direct — -xabans block Xa, dabigatran/argatroban/bivalirudin block thrombin: fast on and off, specific antidotes or none
Where a drug enters the cascade predicts its onset, monitoring and antidote.
- VII (4–6 h) and protein C (8 h) fall first — early INR rise, early hypercoagulable window
- II (60 h) falls last — full warfarin effect takes days, so heparin bridges the start
This is also why skin necrosis appears in the first week.
Practice questions
Q1A 67-year-old man receiving unfractionated heparin after hip surgery has a platelet count that falls from 260,000 to 110,000/µL on day 7. That evening his left calf swells and ultrasound shows a new DVT.
What explains both the thrombocytopenia and the thrombosis?
- A.Heparin directly suppresses platelet production in the marrow
- B.IgG against heparin–PF4 complexes activates platelets through Fc receptors
- C.Heparin depletes antithrombin, causing consumptive coagulopathy
- D.Dilution from intravenous fluids
- E.Heparin inhibits protein C activation
Show answer
B. IgG against heparin–PF4 complexes activates platelets through Fc receptors — In HIT, IgG binds the heparin–PF4 complex and engages platelet Fc receptors, activating platelets, which release more PF4 and procoagulants; the antibody-coated platelets are cleared, so the count falls while thrombosis rises. All heparin must stop, and a non-heparin anticoagulant such as argatroban, bivalirudin or fondaparinux is started. Fondaparinux binds antithrombin but not PF4 and does not react with HIT antibodies.
Q2A 52-year-old woman starts warfarin for a DVT without overlapping heparin. On day 4 she develops painful purple patches on her thigh that progress to necrosis. She is later found to have inherited protein C deficiency.
Why did this happen early in therapy?
- A.Warfarin is metabolized by CYP2C9 to a toxic metabolite
- B.Factor II falls first, causing bleeding into the skin
- C.Warfarin directly damages dermal capillaries
- D.Vitamin K deficiency from poor diet
- E.Protein C, with a short half-life, falls before factors II, IX and X, causing a transient hypercoagulable state
Show answer
E. Protein C, with a short half-life, falls before factors II, IX and X, causing a transient hypercoagulable state — Warfarin blocks VKORC1, so all vitamin K-dependent proteins decline according to their half-lives: protein C (about 8 h) before factor II (60 h) and X (48–72 h). The resulting acquired protein C deficiency makes the first days prothrombotic, and inherited protein C or S deficiency raises the risk — the reason heparin overlaps warfarin at the start.
Q3A 74-year-old man taking dabigatran for atrial fibrillation is brought in after a fall with an expanding subdural hematoma. His creatinine clearance is reduced.
Which agent most specifically reverses his anticoagulant?
- A.Idarucizumab
- B.Protamine sulfate
- C.Andexanet alfa
- D.Vitamin K
- E.Aminocaproic acid
Show answer
A. Idarucizumab — Idarucizumab is a humanized antibody fragment that binds dabigatran (and its metabolites) with higher affinity than dabigatran binds thrombin, neutralizing it. Dabigatran is mainly renally cleared, so reduced renal function prolongs its effect; hemodialysis can also remove it. Andexanet is labeled for apixaban and rivaroxaban, protamine for heparin, and vitamin K for warfarin.
Q4A 61-year-old woman with a mechanical mitral valve asks whether she can switch from warfarin to a direct oral anticoagulant to avoid INR checks.
Which statement is correct?
- A.Dabigatran is the preferred replacement for mechanical valves
- B.Apixaban is approved for mechanical valves if the INR is stable
- C.Any DOAC is acceptable once the valve is a year old
- D.Dabigatran is contraindicated with mechanical valves, and warfarin remains the anticoagulant for them
- E.Rivaroxaban is preferred because it needs no monitoring
Show answer
D. Dabigatran is contraindicated with mechanical valves, and warfarin remains the anticoagulant for them — Dabigatran is contraindicated in patients with a mechanical prosthetic heart valve, and rivaroxaban, apixaban and edoxaban are not recommended with prosthetic or mechanical valves. Warfarin is used with valve-specific INR targets (for example 2.5–3.5 for a mechanical mitral valve).
Q5A 45-year-old man with recurrent DVT has very slow INR responses and bleeds on standard warfarin doses. Genotyping shows CYP2C9*3/*3.
What best explains his response?
- A.Increased VKORC1 expression
- B.Faster S-warfarin clearance
- C.Reduced CYP2C9 7-hydroxylation of the more potent S-warfarin
- D.Low vitamin K intake
- E.Antibodies to warfarin
Show answer
C. Reduced CYP2C9 7-hydroxylation of the more potent S-warfarin — CYP2C9*2 and *3 reduce 7-hydroxylation of S-warfarin, so exposure rises and lower maintenance doses are needed; *3/*3 patients may take more than 2–4 weeks to reach the maximum INR for a given regimen. VKORC1 variants also lower dose needs, and CPIC has a level-A guideline for CYP2C9, VKORC1 and CYP4F2 with warfarin.
Sources
- Eliquis (apixaban) — boxed warnings: discontinuation & spinal hematoma — FDA / DailyMed
- Jantoven (warfarin) — current FDA label: boxed bleeding warning, contraindications, missed dose — FDA / DailyMed
- Lovenox (enoxaparin) — FDA label: indications, contraindications, spinal/epidural hematoma — FDA / DailyMed
- Xarelto (rivaroxaban) — FDA label — FDA / DailyMed
- Pradaxa (dabigatran) — FDA label (contraindicated with mechanical heart valves) — FDA / DailyMed
- Andexxa (andexanet alfa) — reversal of rivaroxaban/apixaban (FDA label) — FDA / DailyMed
- Praxbind (idarucizumab) — reversal of dabigatran (FDA label) — FDA / DailyMed
- Heparin sodium injection — FDA label: aPTT target, HIT, contraindications, protamine — FDA / DailyMed
- Protamine sulfate injection — FDA label — FDA / DailyMed
- Open RN Nursing Pharmacology — Ch. 6 (blood coagulation modifiers: heparin, enoxaparin, warfarin, DOACs; ISMP high-alert list) — Open RN (NCBI Bookshelf)
- Warfarin — mechanism, onset, INR targets, skin necrosis — StatPearls (NCBI)
- Heparin — antithrombin mechanism, aPTT monitoring — StatPearls (NCBI)
- Heparin-Induced Thrombocytopenia — StatPearls (NCBI)
- Physiology, Coagulation Pathways — StatPearls (NCBI)
- Deep Venous Thrombosis — DVT and pulmonary embolism; LMWH in pregnancy — StatPearls (NCBI)
- Warfarin Drug Interactions — antimicrobials, amiodarone — StatPearls (NCBI)
- The use of stems in the selection of International Nonproprietary Names (-xaban) — World Health Organization
- Enoxaparin — antithrombin-mediated factor Xa inhibition — StatPearls (NCBI)
- Vitamin K1 (phytonadione) injection — FDA label (boxed warning) — FDA / DailyMed
- Savaysa (edoxaban) — FDA label: boxed reduced efficacy at CrCl > 95 mL/min, discontinuation, spinal/epidural hematoma — FDA / DailyMed
- Arixtra (fondaparinux) — FDA label: boxed spinal/epidural hematoma, contraindications, administration — FDA / DailyMed
- Argatroban injection — FDA label: HIT, aPTT monitoring, hepatic impairment, INR with warfarin — FDA / DailyMed
- Bivalirudin for injection — FDA label: PCI anticoagulant, ACT, acute stent thrombosis — FDA / DailyMed
- Vitamin K — γ-carboxylation and the vitamin K cycle — StatPearls (NCBI)
- Warfarin Toxicity — vitamin K, prothrombin complex concentrate — StatPearls (NCBI)
- Protamine — cationic salt with heparin, partial LMWH reversal — StatPearls (NCBI)
- Table of Pharmacogenomic Biomarkers in Drug Labeling — U.S. FDA
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.